Get the Stockscreener App
0.6769
0.27%
0.0018
Calcimedica Inc stock is traded at $0.6769, with a volume of 47,938.
It is up +0.27% in the last 24 hours and down -7.98% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
See More
Previous Close:
$0.6751
Open:
$0.68
24h Volume:
47,938
Relative Volume:
0.04
Market Cap:
$20.61M
Revenue:
-
Net Income/Loss:
$-19.54M
P/E Ratio:
-0.5179
EPS:
-1.3071
Net Cash Flow:
$-21.18M
1W Performance:
+2.72%
1M Performance:
-7.98%
6M Performance:
+10.48%
1Y Performance:
-76.74%
1-Day Range:
$0.6703
$0.6926
1-Week Range:
$0.6189
$0.6926
52-Week Range:
$0.4606
$7.20
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
0.6704 | 20.75M | 0 | -19.54M | -21.18M | -1.3071 |
VRTX
Vertex Pharmaceuticals Inc
|
515.89 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.63 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.22 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.16 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Calcimedica Inc Stock (CALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
Calcimedica Inc Stock (CALC) Latest News
Woodline Partners discloses 8.1% CalciMedica (CALC) stake and sole voting power - Stock Titan
Armistice Capital (CALC) discloses 3.41M-share, 9.99% holding in CalciMedica - Stock Titan
CalciMedica shares see H.C. Wainwright neutral rating reiterated - Investing.com
Price to book forward of CalciMedica, Inc. – NASDAQ:CALC - TradingView
Price to book forward of CalciMedica, Inc. – BOATS:CALC - tradingview.com
Price to sales forward of CalciMedica, Inc. – NASDAQ:CALC - tradingview.com
Price to sales forward of CalciMedica, Inc. – BOATS:CALC - TradingView
CalciMedica Inc (CALC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K CalciMedica Inc For: 11 August By Investing.com - Investing.com UK
CalciMedica, Inc. 2Q 2026: Net loss $7.7M, EPS $(0.45) — 10-Q Summary - TradingView
CalciMedica (CALC) cuts expenses, raises $15M but flags going concern risk - Stock Titan
CalciMedica Releases Q2 2026 Financial Results - AlphaStreet
CalciMedica, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
CalciMedica stock gains 6% as pulmonary hypertension progress offsets Q2 earnings miss - Yahoo Finance
CalciMedica Secures Up To $49 Million Private Placement To Advance Pulmonary Hypertension Pipeline - Minichart
CalciMedica Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CalciMedica Q2 FY26 net loss widens to $7.65 million - Bitget
CalciMedica stock gains 6% despite earnings miss on pulmonary trial By Investing.com - Investing.com South Africa
CalciMedica stock gains 6% despite earnings miss on pulmonary trial - Investing.com
CalciMedica reports Q2 2026 results: $18.6M cash, net loss $7.7M; financing to fund PH programs - TradingView
CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates - Moomoo
CalciMedica Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
CalciMedica, Inc. SEC Filing (Aug 3, 2026) - Stock Titan
CalciMedica Inc (CALC:UR): Stock Price, Quote and News - bnnbloomberg.ca
CalciMedica aligns with FDA on acute pancreatitis trial design By Investing.com - Investing.com Canada
CalciMedica aligns with FDA on acute pancreatitis trial design - Investing.com
CalciMedica Inc (CALC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CalciMedica Inc (CALC) Institutional Confidence - TradingKey
CALC|CalciMedica Inc|Price:0.760|Chg%:+0.044 - TradingKey
CalciMedica Inc (CALC) Cash Flow - TradingKey
CalciMedica Inc (CALC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CalciMedica Inc (CALC) Valuation: PE, PB & Fair Value Analysis - TradingKey
CalciMedica, Inc. Revenue Breakdown – NASDAQ:CALC - TradingView
CalciMedica Inc (CALC) Income Statement - TradingKey
CalciMedica Inc (CALC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CALC|CalciMedica Inc|Price:0.658|Chg%:-0.001 - TradingKey
CalciMedica Inc. (CALC) Q1 2026 Earnings: Positive EPS Surprise Despite Absence of RevenueEarnings Momentum Score - dars.gov.et
CALC|CalciMedica Inc|Price:0.721|Chg%:-0.039 - TradingKey
CalcimedicaProspectus Covers Resale Of Up To 56,020,287 Shares Of Common StockSEC Filing - TradingView
CalciMedica (NASDAQ: CALC) files to register 56M shares from June 2026 PIPE - Stock Titan
CalciMedica Inc (CALC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Form DEF 14A ATAI Beckley Inc For: 23 July By Investing.com - Investing.com Canada
CalciMedica, Inc. SEC Filing (Jul 23, 2026) - Stock Titan
CalciMedica (NASDAQ: CALC) plans reverse split, 7.5M-share equity plan boost and warrant votes - Stock Titan
Price to earnings forward of CalciMedica, Inc. – NASDAQ:CALC - TradingView
Enterprise value to revenue forward of CalciMedica, Inc. – NASDAQ:CALC - TradingView
CalciMedica (CALC): CVI Investments and Heights Capital disclose 5.1% equity stake - Stock Titan
Enterprise value to EBITDA forward of CalciMedica, Inc. – NASDAQ:CALC - TradingView
CalciMedica (CALC) price target decreased by 24.39% to 10.54 - MSN
Form PRE 14A ATAI Beckley Inc For: 13 July By Investing.com - Investing.com Australia
CalciMedica (NASDAQ: CALC) plans reverse split and warrant votes - Stock Titan
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Calcimedica Inc Stock (CALC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 18 '25 |
Buy |
3.07 |
2,500 |
7,675 |
84,150 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 15 '25 |
Buy |
2.68 |
3,400 |
9,105 |
81,650 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 12 '25 |
Buy |
3.12 |
5,000 |
15,600 |
78,250 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 09 '25 |
Buy |
3.15 |
2,343 |
7,378 |
73,250 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 28 '25 |
Buy |
2.86 |
9,200 |
26,340 |
70,107 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 29 '25 |
Buy |
2.74 |
800 |
2,192 |
70,907 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 21 '25 |
Buy |
2.79 |
3,508 |
9,797 |
60,907 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 20 '25 |
Option Exercise |
1.53 |
15,000 |
22,950 |
179,706 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 20 '25 |
Buy |
2.72 |
2,000 |
5,440 |
57,399 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 19 '25 |
Buy |
2.79 |
1,000 |
2,790 |
55,399 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):